Summary Hereditary non-polyposis colorectal cancer (HNPCC) is linked to an inherited defect in the DNA mismatch repair system. DNA from HNPCC tumours shows microsatellite instability (MSI). It has been reported that HNPCC patients have a better prognosis than patients with sporadic colorectal cancer. We examined whether the presence of MSI in a series of unselected colorectal tumours carries prognostic information. In a series of 181 unselected colorectal tumours, 22 tumours (12%) showed MSI. Survival analysis at 5-10 years follow-up showed no statistically significant difference in prognosis between MSI-positive and -negative tumours. Our results suggest that the MSI phenotype as such is not an independent prognostic factor.
Colorectal cancer (CRC), as all other cancers, seems to be genetically unstable. This instability can be of two kinds: chromosomal instability (CIN) or microsatellite instability (MSI) (Lengauer et al, 1997) . Microsatellites are simple repeats, often a dinucleotide, on non-coding regions of DNA, which could be located within genes or in between genes (Weber and May, 1989) . MSI was first described in a set of unselected CRC (Ionov et al, 1993; Thibodeau et al, 1993) and in hereditary non-polyposis colorectal cancer (HNPCC) Lindblom et al, 1993) . HNPCC is caused by germ-line mutations in genes involved in DNA mismatch repair (MMR) (Kinzler and Vogelstein, 1996) . MSI can be detected in more than 90% of HNPCC tumours Tannergård et al, 1997) . This increased mutation rate is obtained from a defective MMR. HNPCC patients have a better prognosis than sporadic CRC cases (Fujita et al, 1996; Sankila et al, 1996; Myrhoj et al, 1997; Percesepe et al, 1997) . Approximately 12-17% of the unselected tumours also show MSI Ionov et al, 1993; Thibodeau et al, 1993) . Very few mutations in MMR genes have been found in unselected MSI-positive tumours. However, using immunohistochemistry, it has been suggested that the MSI phenotype even in unselected MSI-positive tumours involves lack of MMR gene function. In 14 out of 15 MSI-positive tumours tested, the expression of either hMLH1 or hMSH2 was lacking (Thibodeau et al, 1996; Dietmaier et al, 1997) . A possible mechanism for this can be inactivation of the hMLH1 gene by hypermethylation of its promotor (Kane et al, 1997; Herman et al, 1998) . In accordance with this, patients with sporadic or unselected CRC displaying MSI have been suggested to have a better prognosis than those without (Lothe et al, 1993; Thibodeau et al, 1993; Bubb et al, 1996) . In the current study we wanted to explore further the relations between MSI status and prognosis in unselected CRC, in a large consecutive series of CRC tumours obtained from two surgery clinics, and previously studied for prognostic correlation to various parameters.
MATERIALS AND METHODS

Patients
One hundred and eighty-one unrelated patients with CRC treated at the Departments of Surgery in Uppsala and Falun between 1988 and 1992 were included in the study. Adjuvant preoperative radiotherapy was given to 28 of 62 patients with rectal cancer, and one patient with colon cancer had post-operative adjuvant chemotherapy. The tumours were graded according to the WHO classification system (Morson and Sobin, 1976) , and staged according to the Dukes' classification system (Dukes and Bussey, 1958) . Clinicopathological characteristics are given in Table 1 .
DNA extraction
The samples were frozen and stored at -70°C prior to DNA extraction. DNA was prepared by proteinase-K digestion and phenol-chloroform extraction according to standard procedures.
Microsatellite analysis
Dinucleotide repeats D22S428, D22S272, PDGF and mononucleotide repeats transforming growth factor beta receptor 2 (TGF-β-R II), BAT-26, BAT-25 were used to type all tumours with normal DNA available. For the 86 tumours where no normal DNA was available, only the three mononucleotide markers were used. Primers specific for each locus were used to amplify the repeat and short flanking sequences in template DNA by polymerase chain reaction (PCR). One of the primers was labelled with γ[
32 P]dCTP prior to amplification. PCR was performed on normal and tumour DNA using 50 ng of purified genomic DNA in a final volume of 20 µl. PCR conditions were 95°C for 2 min followed by 35 cycles (94°C for 45 s, 50-60°C for 45 s and 70°C for 1 min), and a final elongation at 70°C for 7 min. Reactions were resolved on urea-formamide polyacrylamide gel and exposed to film.
MSI analysis
Criteria used for MSI in our material are as follows: for samples, where both normal and tumour material were available, six markers were used and MSI defined as an alteration in at least three out of six markers. In 86 samples where constitutional DNA was not available, MSI was defined as an alteration in at least two loci of three tested markers. Tumours showing one alteration but not fulfilling the criteria above called MSI low (MSI-L) (Boland et al, 1998; Perucho, 1999) were considered as MSI-negative tumours in the analysis.
Statistical analysis
Cause-specific survival analysis (death from colorectal cancer) was analysed with the Cox proportional hazard model. Survival curves were constructed using the Kaplan-Meier method, and differences tested using the log-rank test. The χ 2 test was used to test for differences in distribution among groups. Correlation coefficients were calculated when testing correlation among groups (Cox, 1972; Peto et al, 1977) . The statistical software Statistica (Statsoft Inc® version 5.0) was used for the analyses.
RESULTS
In 93 tumours with normal DNA available, we found 11 tumours (12%), with MSI according to the criteria of at least three of six markers used, and in tumours without normal DNA available, 11 tumours (12%) showed MSI according to the criteria of at least two of three mononucleotide markers showing additional bands. Thus, in accordance with previous studies we detected 12% MSI positive tumours in this unselected material of CRC. The mean age of onset of CRC was 69 years (range 39-91).
As expected, of the 22 MSI-positive tumours, the vast majority, 18 (81%), was found in the proximal colon. There was no correlation between MSI status and age or gender (Table 1) . None of the 24 Dukes' D tumours were shown to be MSI-positive. The MSI-positive tumours seem to be of a generally earlier stage. There were no statistically significant differences between MSI-positive and MSI-negative tumours compared by each stage (Table 1) . At follow-up, 68 patients (39%) had died from cancer, or from other causes, but with a known tumour burden. The median survival time of the living patients was 87 months (range 51-106). Univariate survival analyses showed, as expected, a very strong correlation between Dukes' stage and prognosis, and a weaker but statistically significant correlation between tumour differentiation and prognosis (Table 2) .
Survival analysis revealed no statistically significant difference in prognosis between MSI-positive and MSI-negative cases (Table  2) , although a trend towards better survival for MSI-positive cases was observed (Figure 1 ). Survival analysis using Cox proportional hazard model confirmed the lack of significant correlation between MSI-positive tumours and prognosis (data not shown).
DISCUSSION
Our result did not show a significant correlation between MSIpositive unselected colorectal tumours and good prognosis, compared to previous studies (Lothe et al, 1993; Thibodeau et al, 1993; Bubb et al, 1996) . In this study, we used both mononucleotide markers and dinucleotide markers, including BAT-26, to test for MSI status. Previous studies mostly used different numbers of dinucleotide markers. Thibodeau et al (1993) used the criteria one or more alterations out of four markers, and Lothe et al (1993) used two or more alterations out of seven markers. Bubb et al used one or more alterations out of four dinucleotide markers, plus BAT-26. BAT-26, a quasimonomorphic marker (Figure 2) , has been shown to be sufficient alone to give the MSI status of tumours even without normal DNA available Hoang et al, 1997; Zhou et al, 1998) . However, in the study by Bubb et al (1996) BAT-26 was altered in only 58% of the tumours having at least one alteration found with the other four markers. Besides, BAT-26 alone identified three additional tumours in the latter study. Since this report indicated that there could be tumours showing MSI with dinucleotide markers but not BAT-26, we used additional dinucleotide markers (D18S70, D18S461, D18S58, D18S485, D18S483, D18S470, S18S1145, D18S57, D18S66) for the 93 tumours with normal DNA available. This test identified one more tumour to score as MSI-positive, because of dinucleotide markers, while BAT-26 was negative. It also showed that two tumours scored MSI-positive because of alterations in mononucleotide markers should have been MSI negative if only dinucleotide markers were used. It is possible that mono-and dinucleotide markers to some extent will identify different tumours as MSI-positive, but this does not explain the lack of statistically significance results obtained in our study.
We also found seven tumours expressing a low degree of MSI (MSI-L). Five of those had an alteration in one out of three mononucleotide markers and, the other two had one and two alterations, respectively, in six markers.
To test if our criteria for MSI were too stringent, we included the seven MSI-L tumours among the MSI-positive in a separate survival analysis. The correlation obtained was even less (data are not shown), indicating that the lack of correlation to prognosis was not dependent on too strict criteria used for typing a tumour as MSI.
Bubb et al carried out the survival analysis on 169 patients and the hazard ratio of patients with tumours showing MSI to those without was estimated to be 0.39 (Bubb et al, 1996) . Lothe et al who studied 238 tumours using univariate cause specific (death by colorectal cancer) analysis found a significant association between MSI-positive and prolonged survival, the estimated hazard ratio was 0.3 (Lothe et al, 1993) . Thibodeau et al also used univariate analysis of 86 patients with stage A to D colorectal cancer and found a correlation between MSI positive and overall survival (P = 0.02) (Thibodeau et al, 1993) . Relative hazard estimated in our material was 0.55.
A correlation between Dukes' stage and MSI status in one set of tumours could give false significance. In Lothe's and Thibodeau's studies the significance was lost when Dukes' stage was corrected for in the analysis. However, in the Bubb study, where the significance was highest, there was no correlation between Dukes' stage and MSI status. In our study there was no significant difference between MSI-positive and MSI-negative tumours, if compared for each stage. Thus, the differences in prognosis seen in Figure 1 , might be related to tumour stage at diagnosis in the MSI-positive tumours. It is possible that this tendency to a lower tumour stage at diagnosis might be related to a less malignant clinical courses. One explanation for this could be a more efficient immune defence in this group of patients.
In conclusion, although our results suggest that the presence of MSI indicates a weak favourable clinical courses, in a series of consecutive unselected CRC, MSI status is not an independent prognostic factor. 
